A proinflammatory role for IL-18 in rheumatoid arthritis, Journal of Clinical Investigation, vol.104, issue.10, pp.1393-1401, 1999. ,
DOI : 10.1172/JCI7317
Signal Transduction Pathways Involved in Rheumatoid Arthritis Synovial Fibroblast Interleukin-18-induced Vascular Cell Adhesion Molecule-1 Expression, Journal of Biological Chemistry, vol.277, issue.38, pp.34679-34691, 2002. ,
DOI : 10.1074/jbc.M206337200
Interleukin 18 induces angiogenesis in vitro and in vivo via Src and Jnk kinases, Annals of the Rheumatic Diseases, vol.69, issue.12, pp.2204-2212, 2010. ,
DOI : 10.1136/ard.2009.127241
Interleukin-18 as an in vivo mediator of monocyte recruitment in rodent models of rheumatoid arthritis, Arthritis Research & Therapy, vol.12, issue.3, p.118, 2010. ,
DOI : 10.1186/ar3055
Blocking ERK-1/2 reduces tumor necrosis factor ??-induced interleukin-18 bioactivity in rheumatoid arthritis synovial fibroblasts by induction of interleukin-18 binding protein A, Arthritis & Rheumatism, vol.121, issue.3, pp.722-731, 2010. ,
DOI : 10.1002/art.27269
Blocking of interferon regulatory factor 1 reduces tumor necrosis factor ??-induced interleukin-18 bioactivity in rheumatoid arthritis synovial fibroblasts by induction of interleukin-18 binding protein a: Role of the nuclear interferon regulatory factor 1, Arthritis & Rheumatism, vol.7, issue.11, pp.3253-3262, 2011. ,
DOI : 10.1002/art.30583
Caspase-1-dependent pore formation during pyroptosis leads to osmotic lysis of infected host macrophages, Cellular Microbiology, vol.165, issue.11, pp.1812-1825, 2006. ,
DOI : 10.1016/S0962-8924(01)02206-1
Inflammatory Caspases, Cell, vol.117, issue.5, pp.561-574, 2004. ,
DOI : 10.1016/j.cell.2004.05.004
The inflammasome: a caspase-1-activation platform that regulates immune responses and disease pathogenesis, Nature Immunology, vol.164, issue.3, pp.241-247, 2009. ,
DOI : 10.1038/nature07416
Treating inflammation by blocking interleukin-1 in a broad spectrum of diseases, Nature Reviews Drug Discovery, vol.17, issue.8, pp.633-652, 2012. ,
DOI : 10.1038/nrd3800
Activation of Interferon-gamma Inducing Factor Mediated by Interleukin-1beta Converting Enzyme, Science, vol.275, issue.5297, pp.206-209, 1997. ,
DOI : 10.1126/science.275.5297.206
Pro-inflammatory cytokine-induced SAPK/MAPK and JAK/STAT in rheumatoid arthritis and the new anti-depression drugs, Expert Opinion on Therapeutic Targets, vol.23, issue.2, pp.171-183, 2008. ,
DOI : 10.1007/s00018-006-6054-2
Gene expression, synthesis, and secretion of interleukin 18 and interleukin 1?? are differentially regulated in human blood mononuclear cells and mouse spleen cells, Proceedings of the National Academy of Sciences, vol.96, issue.5, pp.2256-2261, 1999. ,
DOI : 10.1073/pnas.96.5.2256
M-CSF induces the expression of a membrane-bound form of IL-18 in a subset of human monocytes differentiating in vitro toward macrophages, European Journal of Immunology, vol.107, issue.6, pp.1618-1626, 2012. ,
DOI : 10.1002/eji.201142173
Tumor necrosis factor (cachectin) is an endogenous pyrogen and induces production of interleukin 1, Journal of Experimental Medicine, vol.163, issue.6, pp.1433-1450, 1986. ,
DOI : 10.1084/jem.163.6.1433
Induction of Jak/STAT signaling by activation of the type 1 TNF receptor, J Immunol, vol.160, pp.2742-2750, 1998. ,
The JAK inhibitor CP-690,550 (tofacitinib) inhibits TNF-induced chemokine expression in fibroblast-like synoviocytes: autocrine role of type I interferon, Annals of the Rheumatic Diseases, vol.71, issue.3, pp.440-447, 2012. ,
DOI : 10.1136/ard.2011.150284
Regulation of inflammatory responses in tumor necrosis factor-activated and rheumatoid arthritis synovial macrophages by JAK inhibitors, Arthritis & Rheumatism, vol.17, issue.12, pp.3856-3866, 2012. ,
DOI : 10.1002/art.37691
Selective Inhibition of JAK1 and JAK2 Is Efficacious in Rodent Models of Arthritis: Preclinical Characterization of INCB028050, The Journal of Immunology, vol.184, issue.9, pp.5298-5307, 2010. ,
DOI : 10.4049/jimmunol.0902819
JAK inhibition with tofacitinib suppresses arthritic joint structural damage through decreased RANKL production, Arthritis & Rheumatism, vol.47, issue.Suppl, pp.3531-3542, 2012. ,
DOI : 10.1002/art.34649
Phase IIb dose-ranging study of the oral JAK inhibitor tofacitinib (CP-690,550) or adalimumab monotherapy versus placebo in patients with active rheumatoid arthritis with an inadequate response to disease-modifying antirheumatic drugs, Arthritis & Rheumatism, vol.63, issue.3, pp.617-629, 2012. ,
DOI : 10.1002/art.33383